Cantor Fitzgerald Lowers RAPT Therapeutics (NASDAQ:RAPT) Price Target to $40.00

RAPT Therapeutics (NASDAQ:RAPT – Get Rating) had its price objective reduced by Cantor Fitzgerald from $44.00 to $40.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Cantor Fitzgerald’s price target indicates a potential upside of 107.36% from the stock’s current price.

Several other equities research analysts also recently weighed in on RAPT. Piper Sandler reduced their price target on RAPT Therapeutics from $34.00 to $33.00 in a report on Thursday, December 8th. Wells Fargo & Company reduced their price objective on RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, January 4th. The Goldman Sachs Group started coverage on RAPT Therapeutics in a report on Thursday, December 1st. They set a “buy” rating and a $27.00 price objective on the stock. HC Wainwright reduced their price objective on RAPT Therapeutics from $50.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Guggenheim started coverage on RAPT Therapeutics in a report on Wednesday, January 4th. They set a “buy” rating and a $55.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, RAPT Therapeutics currently has an average rating of “Buy” and an average target price of $41.38.

RAPT Therapeutics Stock Performance

Shares of NASDAQ RAPT opened at $19.29 on Wednesday. The business’s 50 day moving average price is $27.19 and its 200-day moving average price is $23.36. RAPT Therapeutics has a fifty-two week low of $9.85 and a fifty-two week high of $32.45. The company has a market cap of $576.96 million, a price-to-earnings ratio of -7.56 and a beta of 0.46.

Insider Buying and Selling at RAPT Therapeutics

In other RAPT Therapeutics news, insider William Ho sold 5,000 shares of the stock in a transaction on Thursday, December 29th. The stock was sold at an average price of $18.03, for a total transaction of $90,150.00. Following the sale, the insider now owns 37,650 shares of the company’s stock, valued at approximately $678,829.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other RAPT Therapeutics news, Director Wendye Robbins acquired 2,500 shares of the stock in a transaction dated Tuesday, March 14th. The stock was purchased at an average price of $18.99 per share, with a total value of $47,475.00. Following the transaction, the director now directly owns 14,900 shares of the company’s stock, valued at $282,951. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider William Ho sold 5,000 shares of the firm’s stock in a transaction on Thursday, December 29th. The stock was sold at an average price of $18.03, for a total value of $90,150.00. Following the completion of the sale, the insider now directly owns 37,650 shares of the company’s stock, valued at approximately $678,829.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,742 shares of company stock valued at $532,352. 5.00% of the stock is currently owned by corporate insiders.

Institutional Trading of RAPT Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Alliancebernstein L.P. boosted its position in shares of RAPT Therapeutics by 10.0% in the 4th quarter. Alliancebernstein L.P. now owns 30,900 shares of the company’s stock worth $612,000 after purchasing an additional 2,800 shares in the last quarter. Trustees of Columbia University in the City of New York acquired a new stake in RAPT Therapeutics during the 4th quarter worth about $1,453,000. State of Wisconsin Investment Board lifted its position in RAPT Therapeutics by 18.8% during the 4th quarter. State of Wisconsin Investment Board now owns 28,774 shares of the company’s stock worth $570,000 after acquiring an additional 4,552 shares during the period. Schonfeld Strategic Advisors LLC lifted its position in RAPT Therapeutics by 165.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 281,875 shares of the company’s stock worth $5,581,000 after acquiring an additional 175,585 shares during the period. Finally, Legal & General Group Plc lifted its position in RAPT Therapeutics by 14.1% during the 4th quarter. Legal & General Group Plc now owns 10,278 shares of the company’s stock worth $204,000 after acquiring an additional 1,268 shares during the period.

About RAPT Therapeutics

(Get Rating)

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.